2. Search Result
Search Result
Results for "

inward

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

6

Peptides

7

Natural
Products

5

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108608
    o-3M3FBS

    		Calcium Channel Others
    o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca 2+]i in an agonistic manner .
    o-3M3FBS
  • HY-19434
    trans-ACPD

    Trans-(±)-ACP

    		 mGluR Metabolic Disease
    trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.
    trans-ACPD
  • HY-N2338
    Cholesterol myristate

    Cholesteryl myristate; Cholesteryl tetradecanoate

    		 nAChR GABA Receptor Potassium Channel Endogenous Metabolite Cancer
    Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the nicotinic acetylcholine receptor, GABAA receptor, and the inward-rectifier potassium ion channel.
    Cholesterol myristate
  • HY-N4309A
    Lotusine hydroxide

    		Others Cardiovascular Disease
    Lotusine (hydroxide) is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine (hydroxide) shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .
    Lotusine hydroxide
  • HY-107757
    GMQ hydrochloride

    2-Guanidine-4-methylquinazoline hydrochloride

    		 Sodium Channel Neurological Disease
    GMQ (hydrochloride) is a ASIC (acid-sensing ion) channel activator with an EC50 value of 1.83 mM for ASIC3 at pH 7.4. GMQ (hydrochloride) opens only ASIC3 but no other ASICs at pH 7.4. GMQ (hydrochloride) can be used for neurological disease research .
    GMQ hydrochloride
  • HY-N6868
    Dimethyl lithospermate B

    dmLSB

    		 Sodium Channel Cardiovascular Disease
    Dimethyl lithospermate B (dmLSB) is a selective Na + channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .
    Dimethyl lithospermate B
  • HY-P5887
    Tertiapin-RQ

    		Potassium Channel Neurological Disease
    Tertiapin-RQ is an inward rectifier K + channel blocker peptide with antidepressive effect .
    Tertiapin-RQ
  • HY-N4309
    Lotusine

    		Others Cardiovascular Disease
    Lotusine is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .
    Lotusine
  • HY-12520B
    (R)-SKF 38393 hydrochloride

    (±)-SKF-38393 hydrochloride; SKF-38393A hydrochloride

    		 Dopamine Receptor Potassium Channel Neurological Disease
    (R)-SKF 38393 ((±)-SKF-38393) hydrochloride is a potent and selective D1 dopamine receptor antagonist. (R)-SKF 38393 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channel .
    (R)-SKF 38393 hydrochloride
  • HY-103298
    MNI-caged kainate

    		Endogenous Metabolite Neurological Disease
    MNI-caged kainate is a photoprotected neuroactive amino acid with the activity to generate large inward currents. MNI-caged kainate can be released at the resting membrane potential of Purkinje cells and generate significant inward currents. The release of MNI-caged kainate results in approximately 40% of the current being generated through AMPA receptor activation. MNI-caged kainate is used to study fast synaptic receptor mechanisms. The photorelease time of MNI-caged kainate is in the sub-microsecond range, making it suitable for investigating the mechanisms of fast synaptic transmission .
    MNI-caged kainate
  • HY-116072
    Antiarrhythmic agent-2

    		Calcium Channel Cardiovascular Disease
    Antiarrhythmic agent-2 is a nonspecific Ca 2+ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias .
    Antiarrhythmic agent-2
  • HY-114633
    VU625
    2 Publications Verification

    		 Potassium Channel Others
    VU625 is an inhibitor for potassium channel, that selectively inhibits mosquito Aedes aegypti inward rectifier potassium channel 1 (AeKir), with IC50 of 96.8 nM in HEK293 cell. VU625 can be used in development of insecticide .
    VU625
  • HY-129496
    NP-313

    		Thrombin Cardiovascular Disease
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
    NP-313
  • HY-139064
    NPBA

    		Potassium Channel Neurological Disease Inflammation/Immunology
    NPBA, a potassium K2P channel TASK-3 (KCNK9) agonist, is a tandem pore domain weak inward rectifying K + channel (TWIK2) channel blocker. NPBA suppresses NLRP3 inflammasome activation in macrophages .
    NPBA
  • HY-175556
    CNV-dopamine

    		Dopamine Receptor Neurological Disease
    CNV-dopamine is a photoreleasable D2 receptor-selective agonist. CNV-dopamine activates D2 receptors and induces G protein-coupled inwardly rectifying potassium (GIRK) currents. CNV-dopamine is promising for research of disorders like Parkinson’s disease and addiction .
    CNV-dopamine
  • HY-142050
    (R)-IDHP

    		Calcium Channel Cardiovascular Disease
    (R)-IDHP is an isomer of IDHP, a salvia metabolite that exerts vasorelaxant effects by inhibiting Ca 2+ release and Ca 2+ inward flow in voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. IDHP is used in studies of cardiovascular disease .
    (R)-IDHP
  • HY-178058A
    VU6080824 hydrochloride

    		Potassium Channel Others
    VU6080824 (hydrochloride), a derivative of ML-133 (HY-100230), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35  μM. VU6080824 (hydrochloride) has superior thallium flux and manual patch clamp (MPC) functional potency .
    VU6080824 hydrochloride
  • HY-178058
    VU6080824

    		Potassium Channel Others
    VU6080824 (Compound 5s), a derivative of ML-133 (HY-100230), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35  μM. VU6080824 has superior thallium flux and manual patch clamp (MPC) functional potency .
    VU6080824
  • HY-125176
    G907
    1 Publications Verification

    		 Bacterial Infection
    G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .
    G907
  • HY-175099
    AB-ICA

    		Drug Intermediate Neurological Disease
    AB-ICA is a precursor of AB-FUBICA (HY-117403). AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity .
    AB-ICA
  • HY-17401
    Ranolazine dihydrochloride
    4 Publications Verification

    CVT 303 dihydrochloride; RS 43285

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine dihydrochloride
  • HY-127106
    VU0810464
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    VU0810464 is a potent and selective non-ureaG protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) activator. VU0810464 displays nanomolar potency for neuronal (EC50=165 nM) and GIRK1/4 (EC50=720 nM) channels with improved brain penetration .
    VU0810464
  • HY-12533
    Disopyramide
    2 Publications Verification

    Dicorantil; SC-7031

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide
  • HY-12533B
    Disopyramide hydrochloride

    Dicorantil hydrochloride; SC-7031 hydrochloride

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide hydrochloride is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide hydrochloride blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide hydrochloride inhibits HERG encoded potassium channels. Disopyramide hydrochloride also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide hydrochloride
  • HY-12533A
    Disopyramide phosphate
    2 Publications Verification

    Dicorantil phosphate; SC-7031 phosphate

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate
  • HY-B0280
    Ranolazine
    4 Publications Verification

    CVT 303; RS 43285-003

    		 Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine
  • HY-B0883
    3,6-Diaminoacridine hemisulfate
    3 Publications Verification

    		 Bacterial Fluorescent Dye Potassium Channel DNA/RNA Synthesis Infection Neurological Disease Cancer
    Proflavine hemisulfate is a multifunctional acridine compound. 3,6-Diaminoacridine hemisulfate is an acridine dye and also a DNA inserter. Proflavine hemisulfate is a potent broad-spectrum antibacterial agent, and its mechanism is to insert into bacterial DNA, interfering with replication and transcription, causing bacterial lysis. 3,6-Diaminoacridine hemisulfate is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine hemisulfate can penetrate the stratum corneum of the skin and accumulate in the cell nucleus and long-term exposure may induce skin cancer or other malignant tumors .
    3,6-Diaminoacridine hemisulfate
  • HY-B1741
    3,6-Diaminoacridine
    3 Publications Verification

    		 Bacterial Fluorescent Dye Potassium Channel DNA/RNA Synthesis Infection Neurological Disease Cancer
    Proflavine is a multifunctional acridine compound. 3,6-Diaminoacridine is an acridine dye and also a DNA inserter. Proflavine is a potent broad-spectrum antibacterial agent, and its mechanism is to insert into bacterial DNA, interfering with replication and transcription, causing bacterial lysis. 3,6-Diaminoacridine is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine can penetrate the stratum corneum of the skin and accumulate in the cell nucleus and long-term exposure may induce skin cancer or other malignant tumors .
    3,6-Diaminoacridine
  • HY-17401S
    Ranolazine-d8 dihydrochloride

    CVT 303-dd8 dihydrochloride; RS 43285-d8

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine-d8 dihydrochloride
  • HY-17401R
    Ranolazine dihydrochloride (Standard)

    		Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine (dihydrochloride) (Standard) is the analytical standard of Ranolazine (dihydrochloride). This product is intended for research and analytical applications. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine dihydrochloride (Standard)
  • HY-112705
    VU0529331

    		Potassium Channel Neurological Disease
    VU0529331 is a modestly selective non-GIRK1-containing G protein-gated, inwardly-rectifying, potassium channel (non-GIRK1/X) activator, with EC50s of 5.1 µM and 5.2 µM for GIRK2 and GIRK1/2 in HEK293 cells, respectively, also effective on GIRK4 homomeric channel .
    VU0529331
  • HY-B0280S2
    Ranolazine-d3

    		Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine-d3
  • HY-B0280S
    Ranolazine-d5

    CVT 303-d5; RS 43285-003-d5

    		 Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine-d5
  • HY-B0280S1
    Ranolazine-d8

    		Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine-d8
  • HY-B1741A
    3,6-Diaminoacridine dihydrochloride

    		Bacterial Fluorescent Dye Potassium Channel DNA/RNA Synthesis Infection Neurological Disease Cancer
    Proflavine dihydrochloride is a multifunctional acridine compound. 3,6-Diaminoacridine dihydrochloride is an acridine dye and also a DNA inserter. Proflavine dihydrochloride is a potent broad-spectrum antibacterial agent, and its mechanism is to insert into bacterial DNA, interfering with replication and transcription, causing bacterial lysis. 3,6-Diaminoacridine dihydrochloride is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine dihydrochloride can penetrate the stratum corneum of the skin and accumulate in the cell nucleus and long-term exposure may induce skin cancer or other malignant tumors .
    3,6-Diaminoacridine dihydrochloride
  • HY-W197393
    3,6-Diaminoacridine sulfate

    		Bacterial Fluorescent Dye Potassium Channel DNA/RNA Synthesis Infection Neurological Disease Cancer
    Proflavine sulfate is a multifunctional acridine compound. 3,6-Diaminoacridine sulfate is an acridine dye and also a DNA inserter. Proflavine sulfate is a potent broad-spectrum antibacterial agent, and its mechanism is to insert into bacterial DNA, interfering with replication and transcription, causing bacterial lysis. 3,6-Diaminoacridine sulfate is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine sulfate can penetrate the stratum corneum of the skin and accumulate in the cell nucleus and long-term exposure may induce skin cancer or other malignant tumors .
    3,6-Diaminoacridine sulfate
  • HY-12533R
    Disopyramide (Standard)

    Dicorantil (Standard); SC-7031 (Standard)

    		 Reference Standards Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide (Standard)
  • HY-174282
    RDS-04-010

    		Dopamine Transporter Neurological Disease
    RDS-04-010 is an atypical dopamine transporter (DAT) inhibitor. RDS-04-010 has the effect of inhibiting cocaine intake and seeking behavior. RDS-04-010 exerts its modulatory effect mainly by binding to the inward conformation of DAT, thereby reducing the reinforcing effect of cocaine. RDS-04-010 can be used in the study of cocaine use disorder (CUD) .
    RDS-04-010
  • HY-P2791
    Tertiapin (reduced)

    		Potassium Channel Neurological Disease Inflammation/Immunology
    Tertiapin (reduced) is a kind of synthesis of melittin, its Cys3-Cys14 and Cys5-Cys18 between containing a disulfide bond. Tertiapin (reduced) is a kind of inward rectifier potassium channels blockers, can block the activity of calcium activates large conductance potassium channels. Tertiapin (reduced) can be used for research in diseases such as rheumatoid arthritis and multiple sclerosis .
    Tertiapin (reduced)
  • HY-12533AR
    Disopyramide phosphate (Standard)

    		Potassium Channel Sodium Channel Cardiovascular Disease
    Disopyramide (phosphate) (Standard) is the analytical standard of Disopyramide (phosphate). This product is intended for research and analytical applications. Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate (Standard)
  • HY-177763
    TRPM8 receptor agonist-1

    		TRP Channel Others
    TRPM8 receptor agonist-1 (Example 81) is a TRPM8 receptor agonist. TRPM8 receptor agonist-1 can trigger the inward flow of calcium, sodium and other ions within the cell, causing the cell membrane to depolarize and triggering an action potential. TRPM8 receptor agonist-1 can activate signals related to the swallowing reflex and can be used for the research of oropharyngeal dysphagia .
    TRPM8 receptor agonist-1
  • HY-13422
    Zatebradine hydrochloride
    2 Publications Verification

    UL-FS-49; UL-FS-49CL

    		 HCN Channel Cardiovascular Disease
    Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 values 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .
    Zatebradine hydrochloride
  • HY-B0280R
    Ranolazine (Standard)

    CVT 303 (Standard); RS 43285-003 (Standard)

    		 Reference Standards Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine (Standard)
  • HY-117403
    AB-FUBICA

    		Cannabinoid Receptor Potassium Channel
    AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms .
    AB-FUBICA
  • HY-B0920
    Tolazamide
    2 Publications Verification

    U-17835

    		 Potassium Channel Metabolic Disease Endocrinology
    Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .
    Tolazamide
  • HY-P1218
    Phrixotoxin 3

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
    Phrixotoxin 3
  • HY-13422A
    Zatebradine
    2 Publications Verification

    UL-FS-49 free base; UL-FS-49CL free base

    		 HCN Channel Cardiovascular Disease
    Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 value of 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .
    Zatebradine
  • HY-107717
    MNI-caged-NMDA

    		iGluR Neurological Disease
    MNI-caged-NMDA is a light-sensitive amino acid with rapid release properties suitable for use in the study of fast synaptic receptor mechanisms. MNI-caged-NMDA shows metered release of NMDA receptors, inducing rapid and sustained receptor activation in cerebellar interneurons. MNI-caged-NMDA is able to achieve rapid transient responses and generate large inward currents by local laser photolysis. The use of MNI-caged-NMDA can effectively study neurotransmitter signaling and its inhibitory effects on GABA-A receptors .
    MNI-caged-NMDA
  • HY-13422R
    Zatebradine hydrochloride (Standard)

    		HCN Channel Cardiovascular Disease
    Zatebradine (hydrochloride) (Standard) is the analytical standard of Zatebradine (hydrochloride). This product is intended for research and analytical applications. Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 values 1.96 μM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 μM, 2.21 μM, 1.90 μM and 1.88 μM, respectively .
    Zatebradine hydrochloride (Standard)
  • HY-P1218A
    Phrixotoxin 3 TFA

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
    Phrixotoxin 3 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: